Skip to content

Study of the optimal dialysis session length: a randomized control trial

Study of the optimized methods for the diagnosis and treatment of the cardiovascular disease in maintenance hemodialysis patients: a randomized control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15006574
Enrollment
Unknown
Registered
2015-06-15
Start date
2015-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease, maintenance hemodialys

Interventions

Conventional HD group:4 hours per HD session, three time per week
Extended HD group 1:4.5 hours per HD session, three time per week
Extended HD group 2:5 hours per HD session, three time per week
Extended HD group 3 :6 hours per HD session, three time per week

Sponsors

Zhongda Hospital, Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Adult patients (>=18 years) with end stage renal disease recieving maintaince hemodialysis three times per week and 4-4.5 hours per session for >=6 months; 2) Signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Unable or unwilling to follow the study protocol for any reason; unable or unwilling to provide informed consent; 2) Malignant neoplastic disease; 3) Severe liver dysfuction; 4) Pregnant and lactating women; 5) Scheduled for kideney transplantation, change to peritoneal dialysis; 6) Other conditions that researchers considered unsituable for this trial.

Design outcomes

Primary

MeasureTime frame
The composite of all-cause mortality or non-fatal cardiovascular event;

Secondary

MeasureTime frame
All-cause mortality;Cardiovascular mortality;Unstable angina;Myocardial infarction;Congestive heart failure;Stroke;Change in blood pressure during two-year follow-up;Change in blood pressure variability during two year follow-up;Change in serum CRP during two year follow-up;Change in serum IL-6 during two year follow-up;

Countries

China

Contacts

Public ContactBi-Cheng Liu
liubc64@163.com+86 18001580838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026